These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28500412)

  • 1. [Hereditary breast and ovarian cancer].
    Lax SF
    Pathologe; 2017 May; 38(3):149-155. PubMed ID: 28500412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The contribution of BRCA1 and BRCA2 to ovarian cancer.
    Ramus SJ; Gayther SA
    Mol Oncol; 2009 Apr; 3(2):138-50. PubMed ID: 19383375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA.
    Piombino C; Cortesi L; Lambertini M; Punie K; Grandi G; Toss A
    J Oncol; 2020; 2020():6384190. PubMed ID: 32733558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inherited cancer syndromes in 220 Italian ovarian cancer patients.
    Carnevali I; Riva C; Chiaravalli AM; Sahnane N; Di Lauro E; Viel A; Rovera F; Formenti G; Ghezzi F; Sessa F; Tibiletti MG
    Cancer Genet; 2019 Sep; 237():55-62. PubMed ID: 31447066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.
    Yoshida K; Miki Y
    Cancer Sci; 2004 Nov; 95(11):866-71. PubMed ID: 15546503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary breast cancer: syndromes, tumour pathology and molecular testing.
    Sokolova A; Johnstone KJ; McCart Reed AE; Simpson PT; Lakhani SR
    Histopathology; 2023 Jan; 82(1):70-82. PubMed ID: 36468211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes.
    Tjalma WAA
    Ann Oncol; 2024 Jan; 35(1):138-139. PubMed ID: 37866813
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetics and the Gynecologic Patient.
    Wade KS; Estes JM; Kline RC
    Ochsner J; 2020; 20(4):446-451. PubMed ID: 33408585
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to the Letter to the Editor 'There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes (in regard to "ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes")' by W. Tjalma.
    Sessa C; Paluch-Shimon S;
    Ann Oncol; 2024 Jan; 35(1):139-140. PubMed ID: 37898238
    [No Abstract]   [Full Text] [Related]  

  • 10.
    Gorodetska I; Kozeretska I; Dubrovska A
    J Cancer; 2019; 10(9):2109-2127. PubMed ID: 31205572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically driven predisposition leads to an unusually genomic unstable renal cell carcinoma.
    Scimeca M; Rovella V; Caporali S; Shi Y; Bischof J; Woodsmith J; Tisone G; Sica G; Amelio I; Melino G; Mauriello A; Bove P
    Discov Oncol; 2024 Mar; 15(1):80. PubMed ID: 38512353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation.
    Wong HH; Parkinson C; Ledermann JA; Brenton JD; Merger M; Shaw A; Patterson A; Shafi M; Earl HM
    Gynecol Oncol Case Rep; 2012; 3():7-10. PubMed ID: 24371652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
    Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
    Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline Mutations in Triple-Negative Breast Cancer.
    Hahnen E; Hauke J; Engel C; Neidhardt G; Rhiem K; Schmutzler RK
    Breast Care (Basel); 2017 Mar; 12(1):15-19. PubMed ID: 28611536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.
    Hollis RL; Churchman M; Gourley C
    Onco Targets Ther; 2017; 10():2539-2551. PubMed ID: 28546758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of hereditary breast and ovarian cancer.
    Yamauchi H; Takei J
    Int J Clin Oncol; 2018 Feb; 23(1):45-51. PubMed ID: 29185095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management.
    Lee MV; Katabathina VS; Bowerson ML; Mityul MI; Shetty AS; Elsayes KM; Balachandran A; Bhosale PR; McCullough AE; Menias CO
    Radiographics; 2017; 37(4):1005-1023. PubMed ID: 28548905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for familial cancer risk: Focus on breast cancer.
    Rousset-Jablonski C; Gompel A
    Maturitas; 2017 Nov; 105():69-77. PubMed ID: 28818315
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.